Hi everybody!
Our thread on Frequency Therapeutics has garnered nearly 900,000 views over the years. We've seen hypes come and go on this forum, but so far this one's here to stay. So, you can imagine how excited we are to be able to bring you this content as part of the Tinnitus Talk Podcast: an interview with Carl LeBel, Chief Development Officer of Frequency Therapeutics.
A LOT of work went into this episode. We won't bore you with the details, but this was our most laborious production yet; hopefully the quality speaks for itself!
In this episode, you will learn about the promising Phase 1 trial results for the company's hearing regeneration drug FX-322, the potential benefits for tinnitus, why speech intelligibility should be the primary measure of hearing, and when we might expect to see this treatment hit the market.
Listen on:
- Tinnitus Talk Podcast (incl. timestamps and transcript)
- SoundCloud
- iTunes
- Spotify
We welcome any discussion, but please keep the following in mind when commenting:
- Off-topic comments, i.e. not directly responding to the content of the podcast, will be removed. So please do listen before commenting!
- While we welcome constructive criticism on ideas or policies, we do not tolerate direct attacks on individuals.
This episode was produced, as usual, by @Markku and @Hazel and @Autumnly. Amazing content was contributed by @mrbrightside614 and @FGG. And the transcription was made by the wonderful Axel Schiller, from Regensburg University (from where the EU research actions ESIT and UNITI are managed, of which Tinnitus Hub is a part. Do you want to volunteer as well? Let us know!
We also thank our Patreon supporters for making this podcast possible.
Don't forget to:
Sharing Is Caring
Share the podcast on your social media and with your tinnitus friends!